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Abstract
Introduction: Human epidermal growth factor receptor 2 (HER2)-amplified breast cancer represents a clinically
well-defined subgroup due to availability of targeted treatment. However, HER2-amplified tumors have been
shown to be heterogeneous at the genomic level by genome-wide microarray analyses, pointing towards a need
of further investigations for identification of recurrent copy number alterations and delineation of patterns of allelic
imbalance.
Methods: High-density whole genome array-based comparative genomic hybridization (aCGH) and single
nucleotide polymorphism (SNP) array data from 260 HER2-amplified breast tumors or cell lines, and 346 HER2-
negative breast cancers with molecular subtype information were assembled from different repositories. Copy
number alteration (CNA), loss-of-heterozygosity (LOH), copy number neutral allelic imbalance (CNN-AI), subclonal
CNA and patterns of tumor DNA ploidy were analyzed using bioinformatical methods such as genomic
identification of significant targets in cancer (GISTIC) and genome alteration print (GAP). The patterns of tumor
ploidy were confirmed in 338 unrelated breast cancers analyzed by DNA flow cytometry with concurrent BAC
aCGH and gene expression data.
Results: A core set of 36 genomic regions commonly affected by copy number gain or loss was identified by
integrating results with a previous study, together comprising > 400 HER2-amplified tumors. While CNN-AI
frequency appeared evenly distributed over chromosomes in HER2-amplified tumors, not targeting specific regions
and often < 20% in frequency, the occurrence of LOH was strongly associated with regions of copy number loss.
HER2-amplified and HER2-negative tumors stratified by molecular subtypes displayed different patterns of LOH and
CNN-AI, with basal-like tumors showing highest frequencies followed by HER2-amplified and luminal B cases.
Tumor aneuploidy was strongly associated with increasing levels of LOH, CNN-AI, CNAs and occurrence of
subclonal copy number events, irrespective of subtype. Finally, SNP data from individual tumors indicated that
genomic amplification in general appears as monoallelic, that is, it preferentially targets one parental chromosome
in HER2-amplified tumors.
Conclusions: We have delineated the genomic landscape of CNAs, amplifications, LOH, and CNN-AI in HER2-
amplified breast cancer, but also demonstrated a strong association between different types of genomic
aberrations and tumor aneuploidy irrespective of molecular subtype.
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Breast cancer (BC) constitutes a heterogeneous group of
lesions with differences in clinical presentation, patholo-
gical features and biological behavior. Amplification and
overexpression of the human epidermal growth factor
receptor 2 (HER2) (HER2/neu, ERBB2) oncogene occur
in 15 to 25% of invasive BC [1,2] and define a clinically
important subgroup (HER2+). Patients with HER2+ BC
have traditionally been associated with poor prognosis
[1,3]; however, the advent of HER2-targeted therapies
has changed the natural course of the disease for many
patients, representing one of the success stories of mod-
ern oncology. Unfortunately, not all patients with HER2
+ disease benefit from targeted treatment, and some
develop treatment resistance over time. It has become
evident through microarray-based studies that BC with
genomic amplification of HER2 (HER2-amplified) con-
stitutes a biologically heterogeneous subgroup of tumors
regarding both gene expression patterns and copy num-
ber alterations (CNAs) [4,5]. Such genomic profiles have
predominantly been obtained from array comparative
genomic hybridization (aCGH) [5-7], but more recently
single nucleotide polymorphism (SNP) microarrays have
become increasingly used, allowing simultaneous detec-
tion of both CNAs and allelic imbalance (AI) [8-11].
However, due to disease and data complexity, CNA
information has so far mostly been extracted from SNP
array data and only recently have robust analysis meth-
ods emerged capable of detecting and integrating CNAs
and AI [10,12-14]. Consequently, HER2-amplified BC
has not yet been thoroughly investigated in this respect.
We, therefore, analyzed assembled BC data from differ-
ent repositories and by integrating these results with our
previous study comprising 200 HER2-amplified tumors
[5], we were able to define a core set of significant
CNAs and recurrent amplifications. Furthermore, using
a combination of bioinformatical methods for SNP
arrays and quantitative DNA flow cytometry (FCM) we
delineated the patterns of loss of heterozygosity (LOH),
copy number neutral allelic imbalance (CNN-AI), tumor
ploidy, tumor subclonality and occurrence of monoalle-
lic gene amplification. Data from HER2-amplified
tumors were compared to data from other subgroups of
BC, shedding light on a complex landscape of genomic
alterations in a clinically important disease entity.
Materials and methods
Tumor material
DNA from 26 frozen tumors with HER2 gene amplifica-
tion was extracted as previously described [5]. SNP ana-
lysis was performed at the SCIBLU Genomics Resource
Center [15] using the Illumina (Illumina, San Diego,
CA, USA) Omni 1 M and 2.5 M Quad beadchips (n =5
and 21, respectively) according to manufacturer’s
instructions. The 26 cases are referred to as the Lund-
HER2-SNP set and are part of a previous study of
HER2-amplified BC that was approved by the regional
Ethical Committee in Lund (reg. no. LU240-01 and
2009/658), waiving the requirement for informed con-
sent for the study [5]. In addition, genomic profiles were
obtained from public repositories for 12 studies
[8-11,16-23] comprising 218 primary tumors with ampli-
fication of HER2, and 16 reported HER2-amplified BC
cell lines analyzed by Agilent (Agilent, Santa Clara, CA,
USA) aCGH, Illumina SNP beadchips or Affymetrix
(Affymetrix, Santa Clara, CA, USA) SNP arrays [. HER2-
amplified tumor cases were identified based on genomic
profiles and displayed marked elevation of HER2 copy
number (CN) estimates compared to remaining samples
from respective data set (Figure S1, Additional file 1).
Additionally, 115 of the 218 tumors had public annota-
tions regarding HER2-status, and of these 98% (113)
were annotated as HER2+. Gene expression profiles
were available for 99 of 218 tumor cases. Gene expres-
sion subtypes were assigned based on correlation to
PAM50 [24] gene expression centroids obtained from
Weigelt et al. [25] as further described (Additional file 2
and [26]). Correlation of gene expression data with
genomic alterations was performed as described ([27]
and Additional file 2). Analysis of differential gene
expression for genes in recurrent amplifications was per-
formed as described (Additional file 2). Patient and
tumor characteristics are summarized in Table 1 and
Table S1 in Additional file 1. SNP data for the Lund-
HER2-SNP set are available as series GSE31645 from
Gene Expression Omnibus [28].
SNP and aCGH preprocessing
Affymetrix SNP array data for 108 HER2-amplified
tumors or cell lines were obtained from public reposi-
tories [17,28]. CEL files were normalized using CRMAv2
[29] and ACNE [30] for generation of CN and B allele
frequency (BAF) estimates as further described (Addi-
tional file 2). CN and BAF estimates for 47 HER2-ampli-
fied cases analyzed by Illumina SNP beadchips were
generated using GenomeStudio (Illumina). Illumina
2.5M SNP BAF data were quantile normalized [21] prior
to further analysis. Normalized Agilent 244K data were
obtained for 105 HER2-amplified cases from Gene
Expression Omnibus [28]. Genomic profiles from all
array platforms except the Illumina 2.5 M platform and
GSE17907 were partitioned using Gain and Loss Analy-
sis of DNA (GLAD) [31]. The Illumina 2.5 M platform
was partitioned using Circular Binary Segmentation with
a = 0.001 [32], while already partitioned data for
GSE17907 were obtained from Gene Expression Omni-
bus. All genomic profiles were centralized similarly as
described [18]. Probe annotations for all array platforms
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genomic profiles from different array platforms were
merged to a common 10,000 bp probe set using a modi-
fied version of the method described by Gunnarsson et
al. [34] (Additional file 2). Data processing steps are
further described in Additional file 2.
Identification of AI and significant CNAs
A modified version of the BAF segmentation [12] soft-
ware was used to partition BAF estimates from SNP
arrays. Partitioned BAF estimates were subsequently
integrated with CN data as described (Additional file 2).
Genomic Identification of Significant Targets in Cancer
(GISTIC) [35] analysis was used to identify significant
CNAs using a residual q-value cut-off of 0.05 (Addi-
tional file 2). Only data from the 218 primary tumors
obtained from public repositories were used in GISTIC
analysis. Thus, HER2-amplified cell lines and the Lund-
HER2-set were excluded from GISTIC analysis, the lat-
ter due to overlap with our previous study [5]. Recur-
rent high-level amplifications, excluding 17q, were
defined as the minimal overlap of amplifications with
log2ratio > 1 occurring in ≥ 3% of the 218 samples.
Recurrent high-level amplifications on 17q were defined
from GISTIC regions of gain on 17q due to the high
genomic complexity on this chromosome arm. The frac-
tion of the genome altered by CNAs (CN-FGA) was
defined as previously described [5].
HER2-negative breast cancer SNP data set
A HER2-negative BC reference SNP data set comprising
346 tumors was created by excluding HER2-amplified
cases from the Van Loo [10] and GSE10099 [11] data
sets. SNP array data were processed similarly as for
HER2-amplified cases from respective data set. Gene
expression data were available for all 346 cases, and
samples were classified according to PAM50 gene
expression subtypes (Table S1 in Additional file 1).
Unclassified samples, and the few HER2-negative sam-
ples classified as belonging to the HER2-enriched mole-
cular subtype in the reference data set were excluded
from further analysis, leaving a final number of 308
cases used in subsequent comparisons. The 308 cases
were classified as basal-like (n = 96), luminal A (n = 88),
luminal B (n = 90), and normal-like (n = 34).
GAP analysis
Integrated AI and CN data for primary tumors analyzed
by SNP arrays (99 HER2-amplified, 308 HER2-negative)
merged to the 10,000 bp probe set were subjected to
Genome Alteration Print (GAP) [13] analysis for estima-
tion of allele-specific copy numbers, fraction of aberrant
cells and an in silico tumor ploidy (referred to as GAP-
ploidy hereon). Frequency of gains and losses from GAP
profiles, relative to the GAP-ploidy, as well frequency of
CNN-AI were calculated as described [10]. LOH fre-
quency was defined as described [10] with the addition
that LOH was not inferred for SNPs called as gain. The
fraction of the genome altered by LOH (LOH-FGA) and
CNN-AI (CNN-FGA) were defined similarly as for
CNAs.
Identification of subclonal CN loss events
To estimate the frequency of subclonal CN events in
HER2-amplified and HER2-negative tumors, only
regions identified as CN loss relative to the GAP-ploidy
Table 1 Characteristics of individual data sets used in the present study stratified by microarray platform
Data Set # HER2-amplified Platform BAF
A GISTIC/GAP
B # Cell lines Matching
GEX
ER:
-/+
LN
C:
-/+
Grade:
1/2/3
PR
D:
-/+
GSE10099 [11] 27 Affymetrix 100K Yes Yes/Yes 0 27 11/16 25/0 0/1/10 11/12
GSE16619 [9] 11 Affymetrix 250K Nsp Yes Yes/Yes 0 NA 2/3 3/8 1/3/7 4/1
14 Affymetrix 5.0 No Yes/No 0 NA 5/5 3/9 0/3/11 5/4
Nikolsky [16] 9 Affymetrix 250K Sty Yes Yes/Yes 0 NA NA NA NA NA
GSE19399 [17]* 32 Affymetrix 250K Sty Yes Yes/Yes 6 NA NA NA NA NA
GSE7545 [8] 5 Affymetrix 250K Nsp Yes Yes/Yes 0 NA 1/0 0/5 NA 1/0
GSE13696 [22] 6 Affymetrix 100K Yes No/No 6 NA NA NA NA NA
GSK [23] 4 Affymetrix 250K Nsp Yes No/No 4 NA NA NA NA NA
Van Loo [10] 20 Illumina 109K Yes Yes/Yes 0 20 14/6 5/14 0/7/13 NA
GSE11977 [21] 1 Illumina 550K Yes Yes/Yes 0 NA 0/1 1/0 NA 0/1
GSE20393 [19] 42 Agilent 244K No Yes/No 0 NA 2/1 NA NA 2/0
GSE20394 [18] 15 Agilent 244K No Yes/No 0 7 9/6 5/10 0/6/9 4/11
GSE17907 [20] 48 Agilent 244K No Yes/No 0 45 20/21 12/27 3/10/28 23/18
Lund-HER2-SNP set 5 Illumina 1M Yes No/No 0 NA 4/1 1/4 NA 4/1
21 Illumina 2.5M Yes No/No 0 NA 15/6 13/8 NA 16/5
A BAF, B Allele Frequency.
B Included in GISTIC analysis and/or GAP analysis.
C LN, Lymph node.
D PR, Progesterone receptor.* Cell lines excluded from GISTIC/
GAP analysis.
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set of CN loss regions were identified by selecting loss
regions for which the total GAP CN differed by ≥ 0.6
from another CN loss region. This set of CN loss
regions were filtered so that only regions with: 1) GLAD
partitioned CN log2ratio < -.12, and 2) size > 100 mar-
kers remained. Finally, to reduce influence of small
shifts in the data an absolute difference > 0.2 in GLAD
partitioned log2ratios between the CN loss regions in
the set with the highest and lowest GAP CNs, respec-
tively, were required for the sample to be annotated as
harboring subclonal CN loss.
DNA flow cytometry analysis
DNA FCM data for a cohort of 338 BC patients with
available BAC aCGH and gene expression data
(assembled from [5,36] and unpublished data) were
obtained as previously described [37]. DNA histograms
were evaluated using ModFitLT (Verity Software House,
Topsham, ME, USA) as described [38]. An experimental
tumor ploidy (FCM-ploidy) was calculated as the sum of
each detected peak’s DNA-index times the fraction of
cells present in the peak, representing a measurement of
the total amount of DNA in analyzed samples. Tissues
from diploid tumor cases were verified by touch imprint-
ing and subsequent HE staining to contain cancer cells.
PAM50 molecular classifications and BAC aCGH data
were available for 282 and 234 cases respectively. Patient
and tumor characteristics for FCM analyzed cases are
summarized in Table S1 in Additional file 1.
Results
Repeated observations of significant CNAs and recurrent
amplifications in HER2-amplified breast cancer
GISTIC analysis of 218 primary HER2-amplified tumors
profiled by high-density SNP or oligonucleotide aCGH
identified 80 regions (34 gains and 46 losses) distributed
across all autosomes (Figure 1A, Additional file 3). Of
the 80 GISTIC regions, 17 overlapped with GISTIC
regions identified in our previous study of 200 HER2-
amplified BCs profiled by BAC aCGH [5] using the
same q-value threshold (Additional file 4). Moreover, an
additional 19 GISTIC regions were located in close vici-
n i t y( <2M b p )f r o mp r e v i o u s l yi d e n t i f i e dG I S T I C
regions [5] (Additional file 4 and Figure S2A in Addi-
tional file 5). Taken together this highlights a core set of
genomic regions commonly affected by CNAs in HER2-
amplified BC. Integration of gene expression data with
CN estimates for genes in these core regions identified
numerous genes with significant correlation between
mRNA levels and CN estimates, of which some over-
lapped with findings from our previous BAC study
(Additional file 4). The overall pattern of CNAs in
HER2-amplified BC was mimicked in 16 HER2-
amplified BC cell lines, although with slightly higher
prevalence in cell lines, and with a few discrepancies, for
example, more frequent losses on chromosome 2 in cell
lines (Figure S2B in Additional file 5). The shortest
region of amplification, including the complete HER2
gene, was delineated to 59,004 bp (chr17:35087594-
35146597, hg18 coordinates) comprising HER2,
C17orf37 , and parts of the PERLD1 gene (Figure S2C-E
in Additional file 5). Notably, the shortest region of
amplification overlap did not include GRB7,i nc o n t r a s t
to two previous reports [5,20].
Corroborating our previous findings using BAC aCGH
[5], we found: 1) four GISTIC regions stratifying HER2-
amplified cases based on estrogen receptor (ER)-status
of which two were in the same genomic regions identi-
fied by BAC aCGH (Figure S2F in Additional file 5), 2)
no difference in CN-FGA between ER-negative and ER-
positive tumors, 3) 14 recurrent high-level amplifica-
tions, excluding chromosome 17, of which eight over-
lapped directly or were in close proximity to BAC
aCGH findings with similar frequencies (Additional file
6), and 4) similar frequency (19%) of amplifications in
the centromeric region of chromosome 17, (17p11.1-
17q11.1, CEP17-amplification). Additionally, GISTIC
was used to delineate the complex pattern of amplifica-
tion on chromosome 17q, identifying nine regions of
gain that all comprised cases with high-level amplifica-
t i o n( A d d i t i o n a lf i l e6 ) .O ft h e s en i n er e g i o n s ,t h r e e
overlapped directly with our previous BAC study, and
two were in close proximity (< 500 kbp) (Additional file
6). Integration of gene expression data with CN esti-
mates for genes in recurrent amplifications identified
numerous genes with significant correlation between
mRNA levels and CN estimates (Additional file 6).
Notably, the majority of correlated genes were also
found to be correlated in our previous study (Additional
file 6). In combination with analysis of differential
mRNA expression between amplified and non-amplified
cases for a set of evaluable genes in the recurrent ampli-
fications (Additional file 6), these analyses confirm the
gene dosage dependence of specific genes recurrently
amplified in HER2-amplified BC.
To investigate whether observed frequencies of CN
gain and loss for the 218 cases were biased due to dif-
ferences in tumor ploidy and aberrant cell content we
calculated the frequency of CN gain and loss in relation
to an in silico tumor ploidy (GAP-ploidy) for 99 cases
analyzed by SNP arrays (Figure 1B). Reassuringly, we
found a highly similar pattern of CNAs for these 99
cases (Figure 1B vs. Figure 1A). This finding is in con-
trast to a recent report using a similar bioinformatical
approach in a smaller data set [10].
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The pattern of LOH and CNN-AI in HER2-amplified
BC were delineated through GAP analysis of 99 cases
analyzed by SNP arrays similarly as described [10]. As
expected, LOH was most frequent in regions com-
monly affected by CN loss, for example, 8p, 17p, 9p,
18q and 13q (Figures 2A and 1B). Interestingly, the
frequency of CNN-AI was more evenly distributed
across chromosomes and seldom exceeded 20%. The
highest CNN-AI frequency in HER2-amplified tumors
was observed in a region on 11q close to the
centromere (approximately 30% CNN-AI) (Figure 2B).
The combination of CNN-AI and CN loss calls derived
from GAP analysis (Figure 1B) for the 99 tumors
revealed that genomic alterations involving loss of at
least one allele were highly frequent (> 60% of cases)
in genomic regions on 17p, 8p, and 17q21.3-q22 (Fig-
ure 2C). Stratification of the 99 cases into six clinico-
pathological subgroups show e dt h a tt h ef r a c t i o no ft h e
genome affected by LOH and CNN-AI were less fre-
quent in HER2-amplified ER-positive tumors compared
to ER-negative tumors (P = 0.1 and 0.05 respectively,
Wilcoxon’s test) (Figure 2D, E).
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amplified tumors using log2ratio ± 0.12 as thresholds for CN gain and loss respectively. Blue regions indicate significant CNAs identified by
GISTIC analysis. (B) Frequency of copy number gain (red) and loss (green) across 99 HER2-amplified tumors analyzed by SNP microarrays. Copy
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ciated with higher CN-FGA fractions and worse out-
come [5]. However, whether such tumors also harbor
more LOH or CNN-AI events compared to DNA
diploid cases or tumors with low CN-FGA have not
been fully elucidated. Among the 99 HER2-amplified
tumors we found that cases with lower GAP-ploidy
(estimated to be diploid or near diploid), with the
exception of hypodiploid cases, harbored less LOH and
CNN-AI events, as well as less CNAs compared to cases
with higher GAP-ploidy (Figure 2F).
Pattern of allelic imbalance in HER2-amplified compared
to HER2-negative breast cancer
The heterogeneous nature of BC stresses the importance
of proper tumor stratification for evaluation of differ-
ences between subgroups of BC. To compare the pattern
of LOH and CNN-AI in HER2-amplified tumors to other
BC subgroups, we performed a similar GAP analysis for
the HER2-negative SNP microarray reference data set
stratified by PAM50 subtypes (Additional files 1 and 7).
Joint analysis of HER2-amplified and HER2-negative
cases revealed significant differences between subgroups
(Figure 3). Basal-like tumors displayed the highest FGA
values for LOH and CNN-AI, followed by luminal B and
HER2-amplified/HER2-enriched cases, while luminal A
cases displayed the lowest values (Figure 3). Notably,
there were no significant differences in LOH-FGA and
CNN-FGA values between HER2-enriched tumors strati-
fied by ER-status (P = 0.22 and 0.39 respectively, Wilcox-
on’s test, Figure 3). With the exception for hypodiploid
cases (GAP-ploidy clearly < 2), HER2-negative tumors
showed increasing fractions of LOH, CNN-AI and CNAs
with increasing GAP-ploidy similar to HER2-amplified
cases (Additional file 8).
DNA ploidy and fraction of aberrant tumor cells in HER2-
amplified compared to HER2-negative breast cancer
To investigate the pattern of DNA ploidy in HER2-
amplified tumors compared to other subgroups of BC
we first analyzed FCM derived DNA histograms from
338 external cases with connected gene expression and
BAC aCGH data (Table S1 in Additional file 1). Stratifi-
cation of the 338 tumors by PAM50 subtypes revealed
differences in the distribution of FCM-ploidy between
subtypes. For instance, the luminal A and normal-like
subtypes showed the highest proportions of FCM-ploidy
values close to 2N (most often diploid) (Figure 4A). In
contrast, basal-like tumors showed a clear bimodal
appearance with peaks at 2N and around 2.5N (Figure
4A). Furthermore, the HER2-enriched subtype showed a
high proportion of cases with FCM-ploidy around 3N,
while luminal B tumors showed pronounced peaks at
2N and around 2.6N (Figure 4A). Similar patterns were
observed when comparing FCM-ploidy from 84 HER2-
amplified tumors with 150 cases without amplification
of HER2 (determined by BAC aCGH) stratified by
PAM50 subtypes (Figure 4B). An exception was that the
peak at 3N was less pronounced in HER2-amplified
cases when viewed as a single entity (Figure 4B) com-
pared to HER2-enriched cases (Figure 4A). GAP-ploidy
estimates for 407 cases (99 HER2-amplified and 308
HER2-negative with subtype classification) analyzed by
SNP arrays showed patterns similar to DNA-FCM
results. Again, a bimodal distribution was observed for
basal-like tumors, a predominantly diploid pattern for
luminal A and normal-like tumors, and a more complex
pattern for luminal B and HER2-amplified tumors with
peaks at 3N and higher (Figure S5A in Additional file 9).
Interestingly, stratification of the 84 FCM analyzed
HER2-amplified cases by ER-status revealed differences,
in that ER-negative cases displayed a more pronounced
bimodal distribution of FCM-ploidy estimates similar to
HER2-negative basal-like tumors, while the 3N peak was
most pronounced in HER2-amplified ER-positive cases
(Figure 4C). A similar bimodal distribution of GAP-
ploidy estimates was observed for 28 annotated ER-
negative HER2-amplified tumors analyzed by SNP
arrays, although with a shift towards 3N for the second
peak (Figure S5B in Additional file 9). In contrast, the
concordance between GAP-ploidy and FCM-ploidy dis-
tributions from the two different patient cohorts were
poorer for HER2-amplified ER-positive tumors (Figure
4C and Figure S5B in Additional file 9).
Although quantitative DNA FCM analysis can accu-
rately detect and quantify DNA aneuploid cell popula-
tions, it cannot delineate the proportion of, for example,
diploid cancer cells versus diploid non-tumor cells. To
investigate the fraction of aberrant cells in HER2-ampli-
fied and HER2-negative BC stratified by PAM50 sub-
types, we compared aberrant cell estimates obtained
from GAP analysis for 99 versus 308 cases analyzed by
SNP microarrays, respectively. Small differences in aber-
rant cell estimates between subtypes were observed (P =
0.003, ANOVA), with the luminal subtypes, generally
associated with ER-positivity, showing the highest esti-
mates (P = 0.00004, Wilcoxon’s test, luminal subtypes
versus remaining subgroups combined) (Figure 4D). In
contrast, no difference in aberrant cell percentages was
observed for stratification of all HER2-amplified cases,
or HER2-enriched tumors by ER-status (P =0 . 9 5a n d
0.14 respectively, Wilcoxon’s test).
Tumor subclonality in breast cancer revealed by SNP
array analysis
BC often display extensive intra-tumor heterogeneity
regarding, for example, cell size, morphology, proliferation
and genomic alterations [39-41]. To a certain extent,
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Page 7 of 15aCGH and SNP arrays allow detection of CNAs that differ
in prevalence among analyzed cells. To investigate the pre-
valence of subclonal CN events in HER2-amplified versus
HER2-negative BC, we employed a conservative approach
limited to larger CN deletions only (see Material and
methods). In the 99 HER2-amplified BCs analyzed by SNP
arrays, this approach identified 39 cases (39%) with subclo-
nal CN loss. By comparison, in the 308 HER2-negative
cases 98 samples (32%) were identified as having subclonal
CN loss. Differences in the prevalence of subclonal CN
loss events were observed between HER2-amplified/
HER2-enriched and HER2-negative cases stratified by
molecular subtype (P =3×1 0
-6, Chi-square test). HER2-
amplified/HER2-enriched cases together with basal-like
tumors showed the highest prevalence of subclonal CN
loss, followed by luminal B tumors, while luminal A and
normal-like tumors displayed the lowest fractions (Figure
5). Subclonal CN loss was associated with higher fractions
of LOH, CNN-AI, CNAs and higher GAP-ploidy for
HER2-amplified, HER2-amplified/HER2-enriched, luminal
A and luminal B cases (P < 0.05, Wilcoxon’s tests). For
basal-like tumors subclonal CN loss was significantly
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Figure 3 Fraction of LOH and CNN-AI in HER2-amplified and HER2-negative breast cancer.( A) Fraction of the genome affected by LOH
for HER2-amplified cases stratified by PAM50 subtype and ER-status compared to HER2-negative cases stratified by PAM50 subtypes. Top-axis
indicates number of samples in each group. A significant difference in LOH-FGA is observed between HER2-amplified and HER2-negative cases
stratified by PAM50 subtype (P =7×1 0
-30, ANOVA). A similar difference was observed when comparing LOH-FGA estimates for all HER2-
amplified tumors against HER2-negative cases stratified by PAM50 subtype (P =3×1 0
-33, ANOVA). (B) Fraction of the genome affected by CNN-
AI for HER2-amplified cases stratified by PAM50 subtype and ER-status compared to HER2-negative cases stratified by PAM50 subtypes. Top-axis
indicates number of samples in each group. A significant difference in CNN-FGA is observed between HER2-amplified and HER2-negative cases
stratified by PAM50 subtype (P =4×1 0
-10, ANOVA). A similar difference was observed when comparing CNN-FGA estimates for all HER2-
amplified tumors against HER2-negative cases stratified by PAM50 subtype (P =2×1 0
-10, ANOVA).
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Figure 4 Tumor ploidy and percentage of aberrant tumor cells in HER2-amplified compared to HER2-negative breast cancer.( A)
Distribution of FCM-ploidy across PAM50 subtypes for 260 cases with concurrent gene expression data. Of the 34 HER2-enriched cases, 21 had
concurrent BAC aCGH data. 19 of these 21 cases showed amplification of HER2 by BAC aCGH, (B) Distribution of FCM-ploidy across 219 breast
cancer samples grouped as HER2-amplified by BAC aCGH, or HER2-negative by BAC aCGH and further stratified by PAM50 subtype. (C)
Distribution of FCM-ploidy for 84 HER2-amplified cases stratified by ER-status. (D) Distribution of percentage of aberrant cells estimated by GAP
analysis of 407 breast cancers across HER2-amplified tumors and HER2-negative tumors stratified by PAM50 subtypes and ER-status. A significant
difference in aberrant cell estimates is observed between HER2-amplified and HER2-negative cases stratified by PAM50 subtype (P = 0.003,
ANOVA). A similar difference was observed when comparing aberrant cell estimates for all HER2-amplified tumors against HER2-negative cases
stratified by PAM50 subtype (P = 0.02, ANOVA). In A to C, curves were generated by an Epanechnikov smoothing kernel with 0.08 smoothing
bandwidth.
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Page 9 of 15associated with higher CN-FGA fractions and higher
GAP-ploidy (P < 0.0001, Wilcoxon’st e s t ) ,w h i l eo n l y
weakly associated with higher LOH-FGA fractions (P =
0.11, Wilcoxon’s test).
High-level amplification events appear as monoallelic in
HER2-amplified breast cancer
Genes residing in regions subjected to genomic amplifi-
cation are oncogene candidates and gene amplification
may occur through different mechanisms. SNP arrays
offer the possibility to dissect the gene amplification
process on an allele specific level as demonstrated by
LaFramboise et al.[ 4 2 ] .I nap a n e lo fl u n gc a n c e r
tumors and cell lines essentially all amplification events
appeared to be monoallelic; that is, gene amplification
exclusively involved only one of the two parental chro-
mosomes [42]. To investigate whether this observation
stands true also in HER2-amplified BC, we aimed to
identify more focal high-level amplification events in the
Illumina Lund-HER2-SNP set by selecting only smaller
segments (> 50 kbp) with a high partitioned CN log2ra-
tio (> 0.7). These criteria identified 108 segments among
the 26 cases. Integration of partitioned CN and mBAF
values [12] for these 108 segments showed that the
absolute majority of them displayed simultaneously high
CN and mBAF values (Figure 6A). These results suggest
that high-level amplifications involve only one of the
parental chromosomes also in HER2-amplified BC.
In contrast to the less frequent and more focal high-
level amplifications, amplifications involving a larger
part of a chromosome arm but with a lower number of
additional gene copies are more frequent in BC. To
investigate whether such amplification events also pre-
ferentially target one parental chromosome, we identi-
fied 90 cases from the 99 HER2-amplified tumors
analyzed by SNP arrays that harbored 835 genomic
regions > 2 Mbp and with a total CN > 3 compared to
the estimated GAP-ploidy for respective sample. Similar
to high-level amplifications, the majority of identified
events displayed amplification of predominantly one of
the two parental chromosomes (Figure 6B).
Discussion
HER2+ BC represents an important clinical subgroup of
the disease due to availability of effective targeted ther-
apy both in the adjuvant and metastatic setting. Clini-
cally, the subgroup is defined by HER2 gene
amplification and/or protein overexpression; however,
genome-wide molecular analyses have shown that BC
with genomic amplification of HER2 (HER2-amplified
BC) is heterogeneous with regards to gene expression
patterns, CNAs and outcome [4,5,20]. Thus, further
characterization of HER2-amplified tumors at the gene
level may have implications for improved diagnosis,
prognosis and prediction.
Here we report the first integrated analysis of CNAs
and AI in a large cohort of HER2-amplified BC profiled
by high-density genomic microarrays, allowing a com-
prehensive description of the genomic landscape of
CNAs, amplifications, LOH and CNN-AI. When com-
paring results to our previous study of 200 HER2-ampli-
fied tumors profiled by BAC aCGH [5], we corroborated
several previous findings regarding, for example, amplifi-
cations, and found a striking similarity in the overall
pattern of CN gain and loss. By comparing significant
CNAs identified by GISTIC analysis in the current and
f o r m e rs t u d y[ 5 ] ,w ew e r ea b l et od e f i n eac o r es e to f
genomic regions commonly affected by CN gain and
loss in HER2-amplified BC across different genomic
microarray platforms that may serve as a list of potential
targets for further studies (Additional file 4). Differences
between the two studies mayb ee x p l a i n e db yu s a g eo f
different array platforms, data analysis methods and
cohort composition. Importantly, however, the
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Figure 5 Prevalence of subclonal CN loss in breast cancer.
Prevalence of subclonal CN loss was estimated in 99 HER2-amplified
cases and 308 HER2-negative cases with PAM50 subtype
classification analyzed by SNP arrays revealing differences in the
frequency of subclonal CN loss events between subgroups. Top-axis
indicates total number of cases for each bar. P-value was calculated
using the Chi-square test for indicated groups.
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Page 10 of 15concordance between our two studies emphasizes that
evaluation of CNAs in a heterogeneous subgroup such
as HER2-amplified BC needs to be performed in large
sample sets in order to pinpoint recurrent alterations.
Genome-wide analyses of LOH, CNN-AI, tumor
ploidy, fraction of aberrant cells and subclonal CN
events utilizing genomic microarrays have been scarce
in BC due to the often high sample complexity, lack of
appropriate analysis methods and low sample numbers.
In the current study, we applied GAP [13] to SNP array
data in combination with conventional DNA-FCM to
analyze genomic alterations on an allele specific level,
patterns of tumor ploidy, tumor subclonality and frac-
tion of aberrant cells in a large set HER2-amplified and
HER2-negative tumors stratified by molecular subtype.
In HER2-amplified cases as well as HER2-negative sub-
groups the pattern of LOH was, as could be expected
from the LOH definition, strongly associated with the
pattern of CN loss (Figures 1 and 2, Additional file 7).
In contrast, CNN-AI events were more evenly distribu-
ted across chromosomes in HER2-amplified tumors, sel-
dom exceeding > 20% in frequency and not targeting
specific genomic regions (Figure 2). Interestingly, a simi-
lar low and evenly distributed CNN-AI pattern was also
observed in HER2-negative luminal A, luminal B and
normal-like tumors (Additional file 7). In contrast,
basal-like tumors showed slightly higher frequencies
potentially explained by a higher frequency of triploid
cases (3N). This suggests that CNN-AI appears as a less
frequent genome-wide additive event in the majority of
breast cancers. Moreover, in relation to other BC sub-
types the patterns of LOH and CNN-AI were similar to
findings by Van Loo et al. [10], and also mimicked the
general pattern of CN-FGA reported for BC gene
expression subtypes [5,36]. However, based on our joint
analysis of 407 HER2-amplified and HER2-negative
cases, we were not able to corroborate previously
reported subtype specific pattern of aberrant cell esti-
mates [10] (Figure 4D). This discrepancy between stu-
dies warrants further investigation, but indicates that
these types of estimations may be difficult to systemati-
cally reproduce. Interestingly, the finding in the current
study that HER2-amplified and predominantly ER-
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Figure 6 Monoallelic amplification in HER2-amplified breast
cancer.( A) High-level amplifications predominantly show
amplification of one parental chromosome in HER2-amplified breast
cancer. Partitioned mBAF [12] estimates are plotted against
corresponding partitioned CN values for 108 genomic segments >
50 kbp in size and with a partitioned log2ratio > 0.7 from cases in
the Lund-HER2-SNP set, representing high-level amplification
segments in this data set. The color and height of segments on the
z-axis indicate chromosome location. BAF estimates range between
0 and 1 reflecting the proportion of the two parental chromosomes
for a given SNP. Due to the symmetry of BAF profiles for current
genome-wide SNP arrays, BAF profiles may be reflected along the
central 0.5 axis into mBAF estimates [12]. In a normal sample mBAF
values close to 0.5 represent a heterozygous state (AB) for a given
SNP, whereas values close to 1 represent a homozygous state (AA
or BB). In tumor samples allelic imbalances are seen as a deviation
of heterozygous SNPs from 0.5. The amplitude of the deviation is a
function of the type of aberration, fraction of aberrant cells carrying
the aberration and tumor ploidy. Thus, for amplification events in
tumor samples higher mBAF values indicate additional copies of
one of the two parental chromosomes in the amplified region. (B)
Distribution of estimated allele specific copy numbers from GAP
analysis for 835 events in 90 of 99 samples analyzed by SNP arrays,
> 2 Mbp in size and with a total CN > 3 compared to the GAP-
ploidy for respective sample. The latter means that if the GAP-ploidy
of a sample is 2.58 an event must have a total CN > 5.58 to be
included. For each event on the x-axis allele specific copy numbers
for the two parental chromosomes are shown as green and red
bars. The total CN is the sum of the height of the red and green
bars, and is truncated at eight by GAP. GAP returns allele specific
copy numbers as numerical values, for example, 2.5, for possible
identification of sub-clonal events, thus the steps in the plot are not
discrete.
Staaf et al. Breast Cancer Research 2011, 13:R129
http://breast-cancer-research.com/content/13/6/R129
Page 11 of 15negative basal-like tumors show lower aberrant cell esti-
mates is consistent with observations of considerable
lymfocytic infiltration in these subtypes [43-45]. In
agreement with observations in lung cancer [42] we
found that amplifications in HER2-amplified BC were
essentially monoallelic, as amplification preferentially
targeted one of the two parental chromosomes (Figure
6). This form of amplification may be a mechanism for
targeting activating oncogene mutations and has pre-
viously been observed on an individual gene level
[46,47]. The full significance of this putative mechanism,
however, remains to be investigated in more detail
using, for example, rapidly evolving sequencing
techniques.
Aneuploidization is one of the most common proper-
ties of cancer and has generally been associated with
worse prognosis and more advanced disease [48]. In
support of an overall higher genomic complexity for
aneuploid BC, we found that increasing GAP-ploidy was
associated with higher fractions of LOH, CNN-AI and
CNAs, as well as higher occurrence of subclonal CN
loss events irrespective of BC subtype (Figure 2F and
Additional file 8). Not surprisingly, the patterns of DNA
ploidy, subclonal CN events, fractions of LOH, CNAs
and CNN-AI across HER2-amplified and HER2-negative
tumors appear consistent with the overall prognosis for
the subgroups. For instance, luminal A and normal-like
tumors, which generally display the best outcome, are
more frequently diploid and less complex. In contrast,
basal-like, HER2-amplified and luminal B cases display
more complex patterns in line with their poorer out-
come and often higher stage [24,36]. Although both
GAP and a similar method termed Allele-Specific Copy
number Analysis of Tumors [10] allow estimation of in
silico tumor ploidy from SNP array data, both methods
have difficulties in analyzing certain types of samples
[10,13]. To get a more unbiased analysis of the pattern
of DNA ploidy across BC subtypes, we used quantitative
DNA FCM data for 338 unrelated BCs also analyzed by
gene expression microarrays and BAC aCGH. Using this
large sample set we were able to corroborate several
findings by Van Loo et al. [10], as well as results from
our GAP analysis, for example, showing that the mole-
cular BC subtypes display different patterns of tumor
DNA ploidy. Shifts between FCM and GAP-ploidy peak
positions, exemplified by HER2-negative basal-like
tumors (Figures 4A and S5A in Additional file 9), may
be explained by that the latter estimation aims to
account for normal cell contamination, while the former
represents a mere total DNA summarization.
Interestingly, the bimodal distribution of tumor ploidy
displayed by HER2-negative basal-like tumors was also
observed in ER-negative HER2-amplified tumors, and in
ER-negative tumors in general irrespective of subtype
(data not shown). These findings imply that the evolu-
tionary hypothesis for basal-like tumors suggested by
Van Loo et al. [10], of a reduction from a diploid to a
partial haploid state followed by whole-genome duplica-
tion, is not limited to a specific molecular subtype but
appears to be more general for ER-negative BC. This
apparently more general difference in DNA ploidy pat-
terns between ER-positive and negative BC most likely
explain differences in LOH and CNN-AI fractions
observed between subgroups/subtypes of HER2-ampli-
fied BC as, for example, ER-negative tumors are overre-
presented in the HER2-enriched subtype. The HER2-
enriched subtype has been found to often comprise the
majority of HER2-amplified cases in gene expression
studies. However, based on findings from several recent
studies, including the current one, it appears clear that
1) the HER2-enriched subtype identified by different
single sample predictors is not synonymous with the
clinically defined HER2+ subgroup, 2) the subtype
includes a notable fraction of HER2-amplified ER-posi-
tive cases, 3) HER2-amplified cases are found in all gene
expression subtypes at varying frequencies, and 4)
HER2-negative cases are found in the HER2-enriched
subtype [5,20,24,25]. As an example of the latter, we
found that 7.5% of samples in the 346-sample HER2-
negative SNP reference set were classified as HER2-
enriched by the PAM50 single sample predictor.
In summary, the comprehensive analysis presented
herein confirms and extends several findings about the
reported molecular subtypes of BC, but also emphasizes
the strong association of different types of genomic
aberrations with tumor DNA aneuploidy, irrespective of
subtype. The molecular BC subtypes have repeatedly
been shown to display different CNAs [36,49,50], and,
lately, also differences in fractions of LOH and CNN-AI
[10]. We demonstrate that tumors harboring few CNAs
typically also display less LOH, less CNN-AI, lower
tumor ploidy and less frequent occurrence of subclonal
events, pointing towards an overall lower complexity
irrespective of subtype.
Conclusions
We have conducted a comprehensive survey of genomic
alterations in the largest cohort of HER2-amplified
breast cancer cases profiled by aCGH and SNP arrays
reported to date. Taken together, the results presented
here provide a comprehensive view of the landscape of
genomic alterations including CNAs, LOH, CNN-AI
and tumor DNA ploidy occurring in HER2-amplified
tumors in context of other BC subgroups. Furthermore,
our results emphasize that analysis of genomic altera-
tions in heterogeneous subgroups, such as HER2-ampli-
fied BC, need large sample numbers in order to draw
more definite conclusions.
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Additional file 1: Identification of HER2-amplified cases and patient
and tumor characteristics for reference data sets. A pdf file
containing figure S1 showing HER2 CN estimates for identified HER2-
amplified cases from public repositories, and a table (S1) of patient and
tumor characteristics for HER2-amplified, HER2-negative tumors in the
SNP reference breast cancer data set, and the 338 tumors analyzed by
FCM.
Additional file 2: Supplementary Methods. A Word document
containing supplementary information about used methods and data
processing.
Additional file 3: Significant GISTIC regions identified from analysis
of 218 HER2-amplified breast cancers. An Excel table presenting
significant GISTIC regions and frequency of amplification in these regions,
as well as sample identifiers for the 218 primary tumors used for GISTIC
analysis.
Additional file 4: Recurrent GISTIC regions in HER2-amplified breast
cancer. An Excel table presenting GISTIC regions that overlaps with a
previous study of 200 HER2-amplified cases analyzed by BAC aCGH.
Additional file 5: CNAs in HER2-amplified breast tumors and cell
lines. A pdf file containing six figures, S2A-F, showing the overlap of
GISTIC regions identified in the current and a former BAC aCGH study,
pattern of CNAs in 16 HER2-amplified breast cancer cell lines, shortest
region of amplification including the HER2 gene, HER2-amplified cases
defining the centromeric and telomeric breakpoints for the shortest
region of amplification analysis, and GISTIC regions stratifying HER2-
amplified breast cancer based on ER-status, respectively.
Additional file 6: Recurrent amplifications in HER2-amplified breast
cancer. An Excel table describing recurrent amplifications in the 218
HER2-amplified cases, and the integration with concomitant gene
expression data for genes in amplified regions. Additionally, the overlap
between recurrent amplifications with a previous study of 200 HER2-
amplified cases analyzed by BAC aCGH is presented.
Additional file 7: Frequency of LOH and CNN-AI in HER2-negative
breast cancers analyzed by GAP and stratified by PAM50 subtypes.
A pdf file containing four figures, S3A-D showing frequency of LOH
(upper panel) and CNN-AI (lower panel) for HER2-negative tumors
classified as basal-like, luminal A, luminal B, and normal-like using PAM50.
Additional file 8: Variation of FGA values versus GAP-ploidy for
HER2-amplified and HER2-negative breast cancers. A pdf file
containing five figures, S4A-E, showing the pattern of LOH-FGA, CNN-
FGA and CN-FGA for HER2-amplified cases, HER2-negative basal-like
tumors, HER2-negative luminal A tumors, HER2-negative luminal B
tumors and HER2-negative normal-like tumors respectively.
Additional file 9: Tumor ploidy for HER2-amplified cases estimated
by GAP analysis. A pdf file containing two figures, S5A-B, showing the
distribution of GAP-ploidy estimates for 407 HER2-amplified and HER2-
negative cases stratified according to subtype, and HER2-amplified cases
stratified by ER-status respectively.
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